Abstract
We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive disease and 46 (12%) had chemoresistant disease. Conditioning consisted of chemotherapy-only in 348 patients (BEAM, 164; BEAC, 145; and CBV, 39) and radiochemotherapy with CY and TBI in 47. Median times to granulocyte, platelet recovery and to discharge were significantly shorter in the chemotherapy-only group. Early transplant-related mortality was significantly higher when using CY-TBI. After a median follow-up of 28 months, overall survival (OS) at 8 years of patients conditioned with BEAM or BEAC (58% (95% CI 50–66%)) was more favorable than with CBV (40% (95% CI 24–56%)), and significantly better than with CY-TBI (31% (95% CI 18–44%)). Multivariate analysis revealed that patients conditioned with chemotherapy-only regimens had improved OS, disease-free (DFS) and relapse-free survival (RFS) when compared to those conditioned with CY-TBI. Status at transplant was also a powerful prognostic indicator. We conclude that preparative regimens consisting of chemotherapy-only seem more efficacious than CY-TBI as conditioning for DLCL, because of faster engraftment and greater anti-lymphoma effect, as indicated by improved OS, DFS and RFS. Bone Marrow Transplantation (2001) 27, 405–412.
Similar content being viewed by others
References
Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma Blood 1978 52: 85–95
Philip T, Armitage JO, Spitzer O et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493–1498
Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis New Engl J Med 1987 316: 1499–1505
Vose IM, Armitage JO . Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma Hematol Oncol Clin North Am 1993 7: 577–590
Morrison VA, Petersen BA . High-dose therapy and transplantation in non-Hodgkin's lymphoma Semin Oncol 1999 26: 84–98
Harris NL, Jaffee ES, Stein H et al. A Revised European American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392
Non-Hodgkin's Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma Blood 1997 89: 3909–3918
Salar A, Fernández de Sevilla A, Romagosa V et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases Eur J Hematol 1997 59: 231–237
National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas . Summary and description of a working formulation for clinical usage Cancer 1982 49: 2112–2135
Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma New Engl J Med 1992 327: 1342–1349
Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma New Engl J Med 1993 328: 1002–1006
Cooper IA, Wolf MM, Robertson T et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma J Clin Oncol 1994 12: 769–778
Velázquez WS, McLaughlin P, Tucker S et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 1994 12: 1169–1176
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545
Meehan KR, Pritchard RS, Leichter JW et al. Autologous bone marrow transplantation versus chemotherapy in relapsed non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature Am J Hematol 1995 50: 116–126
Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to frontline chemotherapy: a prospective randomized Italian Multicenter Study J Clin Oncol 1996 14: 534–542
Verdonck LF, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma New Engl J Med 1995 332: 1045–1051
Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation J Clin Oncol 1987 5: 1340–1347
Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation J Clin Oncol 1992 10: 936–941
Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 1995 13: 588–595
Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493–1498
Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle J Clin Oncol 1990 8: 638–647
Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma J Clin Oncol 1993 11: 1846–1851
Goldstone AH, Singer CRJ, Gribben JG et al. Fifth report of EBMTG experience of ABMT in malignant lymphoma Bone Marrow Transplant 1988 3: 33–39
Rapoport AT, Row JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome J Clin Oncol 1993 11: 2351–2361
Stockerl-Goldstein KE, Horning SJ, Negrin RS et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma Biol Blood Marrow Transplant 1996 2: 76–85
Conde E, Sierra J, Iriondo A et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO Bone Marrow Transplant 1994 14: 279–286
Miles-Prince H, Imrie K, Crump M et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups Br J Haematol 1996 92: 880–889
Lee SM, Ryder WDJ, Morgenstern GR et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma Bone Marrow Transplant 1999 24: 271–277
Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide J Clin Oncol 1993 11: 1085–1091
Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study J Clin Oncol 1993 11: 931–936
Nademanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International Index high and high-intermediate risk group Blood 1997 90: 3844–3852
Stoppa AM, Bouabdallah R, Chabonnon C et al. Intensive sequential chemotherapy with repeated blood stem cell support for untreated poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1997 15: 1722–1729
Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma J Clin Oncol 1997 15: 491–498
Pettengell R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1996 14: 586–592
Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2 J Clin Oncol 1997 15: 1131–1137
Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma New Engl J Med 1997 336: 1290–1297
Crilley P, Lazarus H, Topolsky D et al. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies Semin Oncol 1993 20: 50–54
Mounier N, Grisselbrecht C . Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 1998 9: (Suppl. 1) S15-S21
International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994
Gaspard MH, Maraninchi D, Stoppa AM et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and anti-tumor activity in 26 patients with poor-risk malignancies Cancer Chemother Pharmacol 1988 22: 256–262
Linch DC, Vaughan-Hudson B, Anderson L et al. Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large cell lymphoma entered into BNLI trials Ann Oncol 1997 8: (Suppl. 1) S63-S65
Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients J Clin Oncol 1994 12: 2543–2551
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Peto R, Peto J . Asymptotically efficient rank invariant test procedures JR Stat Soc (A) 1972 135: 185–206
Cox DR . Regression models and life tables JR Stat Soc (B) 1972 34: 187–202
Majolino I, Pearce R, Taghipour G et al. Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin's lymphoma: a new matched-pair analysis of the European group for blood and marrow transplantation registry data J Clin Oncol 1997 15: 509–517
Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation Blood 1996 87: 3633–3639
Deeg HJ, Socie G . Malignancies after hematopoietic stem cell transplantation: many questions, some answers Blood 1998 91: 1833–1844
Traweek ST, Slovak ML, Nademanee AP et al. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma Leuk Lymphoma 1996 20: 365–372
Darrington D, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies J Clin Oncol 1994 12: 2527–2534
Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy Blood 1994 83: 3780–3786
Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2535–2542
Milligan DW, Ruiz de Elvira MC, Kolb HJ et al. Secondary leukemia and myelodysplasia after autografting for lymphoma: results from the EBMT Br J Haematol 1999 106: 1020–1026
Blay JY, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the Parma trial Blood 1998 92: 3562–3568
Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled on to the Parma trial J Clin Oncol 1998 16: 3264–3269
Author information
Authors and Affiliations
Additional information
for the GEL/TAMO Spanish Cooperative Group
Rights and permissions
About this article
Cite this article
Salar, A., Sierra, J., Gandarillas, M. et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 27, 405–412 (2001). https://doi.org/10.1038/sj.bmt.1702795
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702795
- Springer Nature Limited
Keywords
This article is cited by
-
A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients
Indian Journal of Hematology and Blood Transfusion (2022)
-
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
Scientific Reports (2021)
-
Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE
Indian Journal of Hematology and Blood Transfusion (2021)
-
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma
Annals of Hematology (2020)
-
Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma
memo - Magazine of European Medical Oncology (2020)